InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)

15.66
Delayed Data
As of Jul 02
 +0.03 / +0.19%
Today’s Change
1.86
Today|||52-Week Range
19.68
+196.59%
Year-to-Date
SECTOR
Industrial Services
INDUSTRY
Engineering & Construction
MARKET CAP
$429.0M

Company Description

Invivo Therapeutics Holdings Corp. is a medical device company, which develops and commercializes groundbreaking technologies for the treatment of spinal cord injuries. Its platform technologies focus on minimizing tissue damage sustained following acute injury and promoting neural plasticity of the spared healthy tissue, which may result in full or partial functional recovery. The company intends to leverage its primary platform technology to develop and commercialize three products: a biocompatible polymer scaffolding device to treat acute spinal cord injuries; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute spinal cord injuries and a biocompatible polymer scaffolding device seeded with autologous human neural stem cells to treat acute and chronic spinal cord injuries. Its additional applications of platform technologies include the potential treatment for, spinal cord injury following tumor removal, peripheral nerve damage, and postsurgical treatment of any transected nerve. Invivo Therapeutics Holdings was founded by Joseph P. Vacanti, Frank M. Reynolds and Robert Langer on November 28, 2005 and is headquartered in Cambridge, MA.

Contact Information

Invivo Therapeutics Holdings Corp.
One Kendall Square
Cambridge Massachusetts 02139
P:(617) 863-5500
Investor Relations:

Employees

Shareholders

Mutual fund holders0.62%
Other institutional-0.45%
Individual stakeholders--

Top Executives

Mark D. PerrinChief Executive Officer & Director
William D'AgostinoSenior Vice President-Operations
Steven F. McAllisterChief Financial Officer
Kristin NeffVP-Clinical Operations & Project Management
Thomas R. UlichChief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account